GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00909051
First received: May 26, 2009
Last updated: January 18, 2012
Last verified: January 2012

May 26, 2009
January 18, 2012
March 2009
December 2010   (final data collection date for primary outcome measure)
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI) [ Time Frame: During observation period of three months ] [ Designated as safety issue: No ]
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI) [ Time Frame: During observation period of three months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00909051 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
  • Patients with untreated or pretreated diabetes mellitus type 2
  • No Glucobay® intake within the last 3 months before documentation of initial visit
  • Exclusion Criteria: contraindication stated in the local Glucobay® product information; warnings and precautions must be considered.
Diabetes Mellitus
Drug: Acarbose (Glucobay, BAYG5421)
Patients with diabetes type 2 newly treated with Glucobay
Group 1
Intervention: Drug: Acarbose (Glucobay, BAYG5421)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15729
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Algeria,   Bosnia and Herzegovina,   Cambodia,   China,   Hong Kong,   India,   Indonesia,   Korea, Republic of,   Malaysia,   Moldova, Republic of,   Pakistan,   Philippines,   Russian Federation,   Singapore,   Thailand,   Vietnam
 
NCT00909051
14284, GB0701
No
Medical Affairs Therapeutic Area Head, Bayer HealthCare AG
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP